Home

­Facilitates graft-versus-leukemia effect (GVL) while minimizing graft-versus-host disease (GVHD).  Background:
Graft versus host disease (GVHD) remains the second leading cause of death following allogeneic hematopoietic stem cell transplant (allo-HCT). In allo-HCT, mature donor T cells in the donor inoculum play a central role in mediating graft-versus-leukemia (GVL) responses against residual leukemia cells that persist after conditioning regimens and also in facilitating donor immune reconstitution. However, the same donor cell population that mediates the GVL effect also causes significant GVHD. Despite decades of research and improvements in post-transplant immunosuppressive therapies, GVHD remains a significant cause of morbidity and mortality in allo-HCT recipients. Current treatments to suppress GVHD following allo-HCT involve general immunosuppressive agents, such as cyclosporine A, that block donor T Cell Receptor (TCR)-mediated signaling and hence, general T cell activation. However, these agents can simultaneously inhibit GVL effects, increasing the chance of relapse and higher mortality.
Technology Overview: 
This SUNY Upstate Medical University technology is a novel inhibitor that explicitly targets the SLP76-ITK interaction and signaling by preventing the SH2 domain of ITK from docking onto SLP76 at tyrosine 145. This peptide specifically disrupts ITK SH2 docking to pY145 of SLP76, a specific scaffold of interest, without inhibiting its activity or affecting its ability to be involved in other pathways. Disrupting this specific interaction is critical for eliminating GVHD while eliciting the desirable GVL effects during allo-HCT. To ensure this peptide enters cells easily and that its cellular localization can be monitored, it incorporates a C-terminal TAT-peptide and an N-terminal fluorescent FITC dye respectively named SLP76145pTYR peptide. Targeting the SLP76:ITK interaction and its downstream factors significantly suppresses GVHD pathogenesis while maintaining GVL effects in an allo-HSCT.  https://suny.technologypublisher.com/files/sites/adobestock_503797799.jpegAdvantages  

• Minimal GVHD but maintains GVL activity.
• Significantly reduces production of inflammatory cytokines and migration to GVHD target organs.

 Applications: 

• Cancer autoimmunity therapy
• Organ transplants
• Many other potential medical treatments

 Intellectual Property Summary:

PCT application filed on 4/9/2021: PCT/US2021/026724
Link: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021207706
Stage of Development:

• TRL 4 –in vivo experiments completed

Licensing Status:
This technology is available for licensing.Licensing Potential: This technology could be of significant value to pharmaceutical companies and others involved in the development and application of medical treatments.
 

Enables high-quality emission computers tomography (ECT) whild reducing the patient's radiation exposure. BackgroundEmission computed tomography (ECT) is an important scientific and medical imaging technique. Clinical applications of ECT include detecting, staging and monitoring response to cancer therapy; detection and risk stratification of cardiovascular diseases; mapping regional blood flow in the brain; bone scans; pulmonary ventilation/perfusion scans; renal scans and many other applications. There is a great need to reduce radiation dose to the patients undergoing ECT examinations. However, dose reduction implies using less ionizing radiation, i.e. fewer gamma photons, which in turn leads to increased noise in the data and in the images reconstructed with conventional methods. Clearly, good quality ECT reconstructions from low-dose ECT examinations, ergo high-noise data, are in high demand. This demand may be met by applying novel advanced ECT reconstruction methods that subdue the noise while preserving diagnostic image quality.Technology Overview:  
This technology uses a computer to reconstruct transaxial images of the patient from projection data. The reconstruction process estimates mean radiotracer activity distribution inside the body of a patient. It is governed by molecular and/or functional processes and allows clinicians to arrive at diagnoses. The algorithm reconstructs the expected activity distribution, while suppressing noise and preserving the spatial resolution in the estimation. This method demonstrates superior performance vs. standard-of-care when the observed data are very noisy or incomplete. It allows clinicians to perform the clinically acceptable ECT examinations with a radiation dose that is two to six times lower than presently used for the standard-of-care ECT imaging. https://suny.technologypublisher.com/files/sites/adobestock_226212015.jpegAdvantages •    Allows lower radiation dose for patients undergoing ECT examinations without compromising the obtained images quality.
•    Provides good quality tomographic image reconstructions under high noise conditions. Applications:  Emission computed tomography (ECT). This is widely used for many medical applications, including:
•    Detecting, staging and monitoring response to cancer therapy.
•    Detection and risk stratification of cardiovascular diseases.
•    Mapping of regional blood flow in the brain.
•    Bone scans.
•    Pulmonary ventilation/perfusion scans.
•    Renal scans
… and many others.  Intellectual Property Summary: This technology is protected by U.S. Patent 9,460,494, “Methods and systems for inverse problem reconstruction and application to ECT reconstruction” 
Stage of Development: TRL 4 – Technology validated in lab Licensing Status: This technology is available for licensing. Licensing Potential: This technology would be of interest to any organization involved in ECT, including:
•    Medical imaging equipment manufacturers
•    Hospitals and medical laboratories
•    Educational and research laboratories
 ­

A novel messenger RNA transcript for prediction of ulcerative colitis and Crohn's disease severity. Background: More than 2 million individuals are diagnosed with Crohn's Disease (CD) and Ulcerative Colitis (UC) in the US every year. While much progress has been made in understanding these diseases, the causes are not fully known and effective treatments remain limited. SUNY Upstate Medical University researchers discovered that a significant percentage of CD and UC patients have dramatically low SHIP1 protein expression, and that a subset of these patients have a novel fusion mRNA transcript that can be used to diagnose and create a treatment plan for those patients that are likely to progress to a severe disease case. Technology Overview: A novel messenger RNA transcript leading to the production of a truncated version of the SHIP1 protein was correlated with increased disease severity in CD and UC, providing an innovative biomarker and method to diagnose and predict the severity of the disease, enabling clinicians to utilize more targeted and stronger therapeutic interventions in specific patient subsets. Advantages:

• Accurate: This transcript is highly specific to a subset of patients prone to severe disease
• Simple: Detection of a specific mRNA transcript

Applications:

• Diagnosis and Prognosis of CD or UC
• Treatment plan accuracy
• IBD, UC, and CD clinical trials

Intellectual Property Summary: Patented, [US10890579B2] Licensing Potential: Licensing, Development partner Licensing Status: This technology is available for licensing. https://suny.technologypublisher.com/files/sites/2022-110adobestock_429215748.jpeg <

A method to precisely control the amount of pressure applied by the fluid flow from the lithotripsy device with a stopcock. Background:
In percutaneous nephrolithotomy, the urologist inserts a needle into the kidney, dilating a tract into which a sheath is inserted. Fluid irrigation and lithotripsy are then used to break up and retrieve kidney stones into a vial, via the sheath.The devices used for this purpose have channels through which suction is applied from an external source to remove the stones; however, they do not have a method for modulating that suction. Instead, someone in the OR has to clamp or bend the suction tubing in order to slow or release the flow.

This is awkward, imprecise and frustrating; too much suction can lead to loss of visualization and air bubbles inside the body; too little suction can also reduce visualization due to the buildup of particles and/or stone fragments in the tubing. These particles and/or fragments sometimes stick to the inside of the suction tubing; they are difficult to remove and this gums up the works, limiting the effectiveness of the suction device.Technology Overview:  
A SUNY Upstate Medical University team has created a method for reducing pressure buildup in the pelvis during endoscopic procedures. First, the researchers determined the optimal shape of a ureteroscope for reducing intrapelvic pressure. Next, they found that by offsetting the endoscope to the side of the access sheath, which contains the endoscope, they could substantially improve fluid outflow and reduce pressure. Finally, the team determined that this displacement could be achieved by adding small, radially emanating projections within the working channel of the scope. They concluded that any endoscope or catheter could be adapted with these projections and that the methods could also be used with bronchoscopes to reduce the disruption in air flow.  https://suny.technologypublisher.com/files/sites/adobestock_4398441972.jpegAdvantages:

• Makes endoscopy safer for patients.
• Reduces pressure that can cause infection, injury, and pain.
• Modifications can be used to adapt any endoscope or catheter

 Applications:

• Reduces pressure buildup during endoscopic procedures.

 Intellectual Property Summary:

• Patent application submitted
• Provisional patent

Licensing Status:
This technology is available for licensing.